← Back to Screener
Metagenomi Therapeutics, Inc. Common Stock (MGX)
Price$1.31
Value ScoreA
Growth ScoreF
Momentum ScoreD
Favorite Metrics
Price vs S&P 500 (26W)-25.86%
Price vs S&P 500 (4W)-7.13%
VGM Score44.41
Market Capitalization$51.20M
All Metrics
Book Value / Share (Quarterly)$3.66
Indicated Dividend (Annual)$0.00
Revenue Growth (3Y)13.59%
Cash Flow / Share (Quarterly)$-2.33
Price vs S&P 500 (YTD)-26.98%
Net Profit Margin (TTM)-384.61%
EPS (TTM)$-2.30
10-Day Avg Trading Volume0.19M
EPS Excl Extra (TTM)$-2.30
EPS (Annual)$-2.36
ROI (Annual)-55.40%
Net Profit Margin (5Y Avg)-1945.52%
Cash / Share (Quarterly)$3.72
Revenue Growth QoQ (YoY)-69.76%
ROA (Last FY)-39.74%
Revenue Growth TTM (YoY)-50.66%
EBITD / Share (TTM)$-2.34
ROE (5Y Avg)-37.04%
Operating Margin (TTM)-415.48%
Cash Flow / Share (Annual)$-2.38
P/B Ratio0.37x
P/B Ratio (Quarterly)0.37x
Net Income / Employee (Annual)$-738,400
EV / Revenue (TTM)1.16x
ROA (TTM)-36.62%
EPS Incl Extra (Annual)$-2.36
Current Ratio (Annual)7.22x
Quick Ratio (Quarterly)6.23x
3-Month Avg Trading Volume0.22M
52-Week Price Return-23.60%
Revenue / Employee (TTM)$187,700
P/S Ratio (Annual)2.03x
Asset Turnover (Annual)0.11x
52-Week High$3.95
Operating Margin (5Y Avg)-2168.10%
EPS Excl Extra (Annual)$-2.36
26-Week Price Return-9.93%
Quick Ratio (Annual)7.03x
13-Week Price Return-15.00%
Total Debt / Equity (Annual)0.00x
Current Ratio (Quarterly)6.43x
Enterprise Value$25.89M
Asset Turnover (TTM)0.10x
Revenue / Employee (Annual)$211,800
Pretax Margin (Annual)-348.77%
Cash / Share (Annual)$4.27
3-Month Return Std Dev54.78%
Net Income / Employee (TTM)$-721,700
ROE (Last FY)-55.40%
EPS Basic Excl Extra (Annual)$-2.36
Receivables Turnover (TTM)44.13x
Total Debt / Equity (Quarterly)0.00x
EPS Incl Extra (TTM)$-2.30
Receivables Turnover (Annual)32.28x
ROI (TTM)-51.23%
P/S Ratio (TTM)2.29x
Pretax Margin (5Y Avg)-1941.11%
Revenue / Share (Annual)$0.68
Price vs S&P 500 (52W)-51.80%
Year-to-Date Return-16.05%
5-Day Price Return0.74%
EPS Normalized (Annual)$-2.36
ROA (5Y Avg)-21.62%
Net Profit Margin (Annual)-348.54%
Month-to-Date Return-1.45%
EBITD / Share (Annual)$-2.43
Operating Margin (Annual)-380.85%
LT Debt / Equity (Annual)0.00x
ROI (5Y Avg)-33.06%
LT Debt / Equity (Quarterly)0.00x
EPS Basic Excl Extra (TTM)$-2.30
P/B Ratio (Annual)0.38x
Pretax Margin (TTM)-385.27%
Book Value / Share (Annual)$4.22
Price vs S&P 500 (13W)-24.75%
Beta1.74x
P/FCF (Annual)3.25x
Revenue / Share (TTM)$0.59
ROE (TTM)-51.23%
52-Week Low$1.24
vGradeA
gGradeF
mGradeD
vgmGradeC
Show chart for
Earnings Surprise History
Q1 26-0.61est. -0.53
Analyst Recommendations
Feb 2026
Mar 2026
Apr 2026
May 2026
4.00
4.00
4.00
4.00
Industry Peers — Biological Products(178)
| Symbol | Value Score | Growth Score | Momentum Score | Price |
|---|---|---|---|---|
MGXMetagenomi Therapeutics, Inc. Common Stock | A | F | D | $1.31 |
| AMGNAmgen Inc | C | C | C | $329.13 |
| GILDGilead Sciences Inc | C | B | C | $131.10 |
| ARGXargenx SE American Depositary Shares | D | A | C | $836.09 |
| RVMDRevolution Medicines, Inc. Common Stock | F | — | A | $163.68 |
| BIIBBiogen Inc. Common Stock | B | D | B | $192.23 |
| BNTXBioNTech SE American Depositary Share | C | C | C | $91.70 |
| MRNAModerna, Inc. Common Stock | C | B | B | $46.06 |
| NBIXNeurocrine Biosciences Inc | C | B | B | $161.00 |
| EXELExelixis Inc | C | B | B | $50.28 |
| KRYSKrystal Biotech, Inc. Common Stock | D | B | B | $298.10 |
About
Metagenomi Therapeutics is a genetic medicines company developing in vivo gene editing therapies using its proprietary metagenomics-derived platform. The company's pipeline targets hemophilia A, refractory hypertension, and cardiovascular diseases. Its comprehensive editing toolbox includes programmable nucleases, base editors, and CRISPR-associated transposases, with the company also pursuing technology licensing for ex vivo cell therapy applications.